## Edgar Filing: VAN NOSTRAND ROBERT L - Form 4

Form 4	TRAND ROBER	ΓL									
January 25, 2019         FORM 4         UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549         Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940         (Print or Type Responses)								N OMB Number: Expires: Estimated burden hou response	urs per		
1. Name and VAN NOS	2. Issuer Name <b>and</b> Ticker or Trading Symbol ACHILLION PHARMACEUTICALS INC [ACHN]				ıg	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X_ Director 10% Owner					
(Last) C/O ACH PHARMA GEORGE	Middle) C., 300	3. Date of Earliest Transaction (Month/Day/Year) 01/23/2019					Officer (give titleOther (specify below)				
(Street) NEW HAVEN, CT 06511			4. If Amendment, Date Original Filed(Month/Day/Year)					6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person			
(City)	(State)	(Zip)	Tab	ole I - Non-l	Derivative	Securi	ities A	cquired, Disposed	of, or Beneficia	lly Owned	
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deem Execution any (Month/Da	ed Date, if	3. Transactio Code (Instr. 8)	4. Securit	ies (A) or of (D) 4 and 5 (A) or	)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect	
Reminder: R	eport on a separate lind	e for each cl	ass of sec	eurities bene	Perso inforr requi	ons wh nation red to	io res conta respo	r indirectly. pond to the colle ained in this forn ond unless the fo atly valid OMB co	n are not rm	SEC 1474 (9-02)	

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

number.

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	ercise any of (Month/Day/Year) ative		4. 5. Number of TransactiorDerivative Code Securities (Instr. 8) Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)		8 E S (1
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	
Stock Option (Right to buy)	\$ 2.18	01/23/2019		A	42,000	<u>(1)</u>	01/23/2029	Common Stock	42,000	

## Edgar Filing: VAN NOSTRAND ROBERT L - Form 4

## **Reporting Owners**

Reporting Owner Name / Add	Relationships					
	Director	10% Owner	Officer	Other		
VAN NOSTRAND ROBERT L C/O ACHILLION PHARMACEUT 300 GEORGE STREET NEW HAVEN, CT 06511	TCALS, INC.	Х				
Signatures						
/s/ Keri Lantz, attorney-in-fact	01/25/2019					

Date

**\*\***Signature of Reporting Person

**Explanation of Responses:** 

\* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) This option vests and becomes exercisable in equal quarterly installments over the one-year period following the date of grant.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.